SPPAM
IOVA icon

Summit Partners Public Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Summit Partners Public Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,555,408
Closed -$12.5M – 129
2024
Q2 		$12.5M Sell
1,555,408
-1,410,579
-48% -$15.1M 0.48% 62
2024
Q1 		$44M Buy
+2,965,987
New +$34.5M 1.51% 23

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Summit Partners Public Asset Management's IOVA Position: Q3 2024 in Review

Summit Partners Public Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 1,555,408 shares — an estimated $12.5M sold.

Summit Partners Public Asset Management first reported a position in IOVA in Q1 2024 and held it in 2 quarters. The position peaked at $44M in Q1 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Summit Partners Public Asset Management reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 1,555,408 Iovance Biotherapeutics shares in Q3 2024, an estimated $12.5M.
  • Summit Partners Public Asset Management first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 2 quarters.
  • Summit Partners Public Asset Management's Iovance Biotherapeutics position peaked at $44M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.